Evaluation of anthelmintic activity in captive wild ruminants by fecal egg reduction tests and a larval development assay.
The effectiveness of anthelmintics was evaluated in four herds of captive ruminants, wapiti (Cervus elaphus), Armenian red sheep (Ovis orientalis), giraffe (Giraffa camelopardalis), and pronghorn (Antilocapra americana), by the use of fecal egg reduction tests (FERTs) and a commercial larval development assay (LDA) designed to evaluate susceptibility or resistance of nematodes to anthelmintics. Haemonchus sp. was the predominant nematode in the red sheep, giraffe, and pronghorn herds, whereas Ostertagia sp. and Trichostrongylus sp. were predominant in the wapiti. The LDA data indicated susceptibility by the worms to benzimidazoles except in the red sheep flock, which showed a high level of resistance. High levels of resistance to levamisole were seen in the worm populations from the wapiti and red sheep, moderate resistance in the pronghorn herd, and susceptibility in the giraffe herd. Worms were susceptible in all four herds to a combination of benzimidazole/levamisole. There was suspected avermectin resistance by Trichostrongylus sp. in the wapiti herd and by Haemonchus sp. in the giraffe. The FERTs agreed with the LDA in showing the Haemonchus in the giraffe was susceptible to fenbendazole and had suspected resistance to ivermectin, whereas Haemonchus in the red sheep and pronghorn were susceptible to ivermectin. There was correlation between the tests evaluating anthelmintics. The LDA is useful as a screening test in the selection of an anthelmintic for use in grazing ruminants, but the effectiveness of a drug in a host species may depend as much on the dose used, and the method of administration, as it does on the parasite's sensitivity to the anthelmintic.
Department of Veterinary Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station 77843-4467, USA.
K E
KE
Young
J M
JM
Jensen
T M
TM
Craig
D000818:Animals; D000866:Antelopes / Q000469:parasitology*; D000871:Anthelmintics / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000032:analysis / Q000096:biosynthesis*; D001188:Artiodactyla / Q000469:parasitology*; D001562:Benzimidazoles / Q000627:therapeutic use; D003670:Deer / Q000469:parasitology*; D004351:Drug Resistance; D005243:Feces / Q000469:parasitology; D005273:Fenbendazole / Q000627:therapeutic use; D006189:Haemonchus / Q000187:drug effects; D007113:Immunity, Innate / Q000276:immunology; D007559:Ivermectin / Q000031:analogs & derivatives / Q000627:therapeutic use; D007814:Larva / Q000187:drug effects / Q000254:growth & development*; D007978:Levamisole / Q000627:therapeutic use; D009348:Nematoda / Q000187:drug effects*; D009349:Nematode Infections / Q000188:drug therapy*; D010028:Ostertagia / Q000187:drug effects; D010270:Parasite Egg Count / Q000662:veterinary*; D012756:Sheep / Q000469:parasitology; D012757:Sheep Diseases / Q000188:drug therapy*; D014254:Trichostrongylus / Q000187:drug effects
D000871:Anthelmintics; D000909:Antibodies, Helminth; D001562:Benzimidazoles; D007978:Levamisole; D005273:Fenbendazole; D007559:Ivermectin; C019264:avermectin; C031000:benzimidazole